What’s Propelling Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) After Lower Shorts Reported?

June 13, 2018 - By Henry Gaston

Vascular Biogenics Ltd. (NASDAQ:VBLT) Logo

The stock of Vascular Biogenics LTD. – Ordinary Shares (NASDAQ:VBLT) registered a decrease of 17.44% in short interest. VBLT’s total short interest was 436,600 shares in June as published by FINRA. Its down 17.44% from 528,800 shares, reported previously. With 116,500 shares average volume, it will take short sellers 4 days to cover their VBLT’s short positions. The short interest to Vascular Biogenics LTD. – Ordinary Shares’s float is 3.07%.

The stock decreased 0.93% or $0.02 during the last trading session, reaching $2.65. About 104,961 shares traded. Vascular Biogenics Ltd. (NASDAQ:VBLT) has declined 60.91% since June 13, 2017 and is downtrending. It has underperformed by 73.48% the S&P500.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company has market cap of $79.23 million. The company??s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. It currently has negative earnings. The Company’s lead product candidate is VB-111, a gene biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Coverage

Among 4 analysts covering Vascular Biogenics (NASDAQ:VBLT), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Vascular Biogenics had 6 analyst reports since March 8, 2018 according to SRatingsIntel. As per Friday, May 18, the company rating was maintained by H.C. Wainwright. As per Thursday, March 8, the company rating was downgraded by H.C. Wainwright. The rating was downgraded by Chardan Capital Markets on Friday, March 9 to “Neutral”. The firm earned “Hold” rating on Thursday, March 22 by H.C. Wainwright. The rating was downgraded by Piper Jaffray to “Hold” on Thursday, March 8. The stock has “Hold” rating by JMP Securities on Thursday, March 8.

More notable recent Vascular Biogenics Ltd. (NASDAQ:VBLT) news were published by: Schaeffersresearch.com which released: “3 Surging Penny Stocks” on June 06, 2018, also Globenewswire.com with their article: “VBL Therapeutics Announces First Quarter 2018 Financial Results” published on May 17, 2018, Streetinsider.com published: “Pre-Open Movers 06/06: (AXON) (VBLT) (SIG) Higher; (AMBA) (IMGN) (OLLI) Lower (more…)” on June 06, 2018. More interesting news about Vascular Biogenics Ltd. (NASDAQ:VBLT) were released by: Seekingalpha.com and their article: “VBL Therapeutics +42% after presenting data on MOSPD2 platform” published on June 05, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: Dow Rises Over 200 Points; Ambarella Shares Slide On Weak Sales Forecast” with publication date: June 06, 2018.

Vascular Biogenics Ltd. (NASDAQ:VBLT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: